MEDICAL FACILITIES CORP (DR.CA) Fundamental Analysis & Valuation
TSX:DR • CA58457V5036
16.97 CAD
+0.01 (+0.06%)
Last: Mar 9, 2026, 07:00 PM
This DR.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, DR scores 6 out of 10 in our fundamental rating. DR was compared to 13 industry peers in the Health Care Providers & Services industry. DR gets an excellent profitability rating and is at the same time showing great financial health properties. DR has a bad growth rate and is valued cheaply. These ratings could make DR a good candidate for value investing.
1. DR.CA Profitability Analysis
1.1 Basic Checks
- DR had positive earnings in the past year.
- DR had a positive operating cash flow in the past year.
- Of the past 5 years DR 4 years were profitable.
- In the past 5 years DR always reported a positive cash flow from operatings.
1.2 Ratios
- DR's Return On Assets of 30.18% is amongst the best of the industry. DR outperforms 92.31% of its industry peers.
- DR has a Return On Equity of 94.43%. This is amongst the best in the industry. DR outperforms 100.00% of its industry peers.
- DR's Return On Invested Capital of 15.42% is amongst the best of the industry. DR outperforms 92.31% of its industry peers.
- DR had an Average Return On Invested Capital over the past 3 years of 16.37%. This is significantly above the industry average of 7.68%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROIC | 15.42% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
- DR has a Profit Margin of 31.60%. This is amongst the best in the industry. DR outperforms 92.31% of its industry peers.
- DR's Profit Margin has improved in the last couple of years.
- DR has a better Operating Margin (15.59%) than 100.00% of its industry peers.
- In the last couple of years the Operating Margin of DR has remained more or less at the same level.
- The Gross Margin of DR (63.75%) is better than 84.62% of its industry peers.
- In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. DR.CA Health Analysis
2.1 Basic Checks
- DR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- DR has less shares outstanding than it did 1 year ago.
- DR has less shares outstanding than it did 5 years ago.
- DR has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.41, we must say that DR is in the distress zone and has some risk of bankruptcy.
- DR has a better Altman-Z score (1.41) than 61.54% of its industry peers.
- The Debt to FCF ratio of DR is 2.05, which is a good value as it means it would take DR, 2.05 years of fcf income to pay off all of its debts.
- DR's Debt to FCF ratio of 2.05 is amongst the best of the industry. DR outperforms 92.31% of its industry peers.
- DR has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
- DR has a Debt to Equity ratio (1.02) which is comparable to the rest of the industry.
- Although DR's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Altman-Z | 1.41 |
ROIC/WACC1.94
WACC7.95%
2.3 Liquidity
- DR has a Current Ratio of 1.79. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.79, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- A Quick Ratio of 1.67 indicates that DR should not have too much problems paying its short term obligations.
- DR's Quick ratio of 1.67 is amongst the best of the industry. DR outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 |
3. DR.CA Growth Analysis
3.1 Past
- DR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.81%, which is quite impressive.
- DR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.68%.
- The Revenue has been decreasing by -3.59% on average over the past years.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
3.2 Future
- The Earnings Per Share is expected to grow by 6.63% on average over the next years.
- The Revenue is expected to decrease by -12.02% on average over the next years. This is quite bad
EPS Next Y49.02%
EPS Next 2Y3.89%
EPS Next 3Y4.45%
EPS Next 5Y6.63%
Revenue Next Year-20.97%
Revenue Next 2Y-16.85%
Revenue Next 3Y-15.97%
Revenue Next 5Y-12.02%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. DR.CA Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 10.48, the valuation of DR can be described as reasonable.
- Based on the Price/Earnings ratio, DR is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 26.46, DR is valued rather cheaply.
- The Price/Forward Earnings ratio is 12.25, which indicates a correct valuation of DR.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of DR indicates a rather cheap valuation: DR is cheaper than 84.62% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of DR to the average of the S&P500 Index (24.65), we can say DR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 12.25 |
4.2 Price Multiples
- DR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DR is cheaper than 100.00% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of DR indicates a rather cheap valuation: DR is cheaper than 92.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.52 | ||
| EV/EBITDA | 4.8 |
4.3 Compensation for Growth
- DR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of DR may justify a higher PE ratio.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y3.89%
EPS Next 3Y4.45%
5. DR.CA Dividend Analysis
5.1 Amount
- DR has a Yearly Dividend Yield of 2.12%.
- DR's Dividend Yield is a higher than the industry average which is at 1.37.
- Compared to an average S&P500 Dividend Yield of 1.82, DR has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.12% |
5.2 History
- The dividend of DR decreases each year by -19.91%.
- DR has paid a dividend for at least 10 years, which is a reliable track record.
- DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
- DR pays out 6.72% of its income as dividend. This is a sustainable payout ratio.
DP6.72%
EPS Next 2Y3.89%
EPS Next 3Y4.45%
DR.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:DR (3/9/2026, 7:00:00 PM)
16.97
+0.01 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-12 2026-03-12
Inst Owners9.84%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap301.39M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts42.22
Price Target16.58 (-2.3%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.12% |
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-5.41%
EPS NQ rev (3m)-5.41%
EPS NY rev (1m)19.3%
EPS NY rev (3m)11.02%
Revenue NQ rev (1m)-1.53%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 12.25 | ||
| P/S | 0.86 | ||
| P/FCF | 4.52 | ||
| P/OCF | 4.16 | ||
| P/B | 2.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.8 |
EPS(TTM)1.62
EY9.55%
EPS(NY)1.38
Fwd EY8.16%
FCF(TTM)3.76
FCFY22.13%
OCF(TTM)4.08
OCFY24.05%
SpS19.78
BVpS6.62
TBVpS-0.87
PEG (NY)0.21
PEG (5Y)N/A
Graham Number15.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROCE | 18.66% | ||
| ROIC | 15.42% | ||
| ROICexc | 19.71% | ||
| ROICexgc | 46.81% | ||
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% | ||
| FCFM | 18.99% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 25.03% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 93.1% | ||
| Profit Quality | 60.09% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.41 |
F-Score6
WACC7.95%
ROIC/WACC1.94
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y49.02%
EPS Next 2Y3.89%
EPS Next 3Y4.45%
EPS Next 5Y6.63%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.97%
Revenue Next 2Y-16.85%
Revenue Next 3Y-15.97%
Revenue Next 5Y-12.02%
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year0.96%
EBIT Next 3Y-5.7%
EBIT Next 5Y-5.28%
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 6 / 10 to DR.CA.
Can you provide the valuation status for MEDICAL FACILITIES CORP?
ChartMill assigns a valuation rating of 8 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
What is the expected EPS growth for MEDICAL FACILITIES CORP (DR.CA) stock?
The Earnings per Share (EPS) of MEDICAL FACILITIES CORP (DR.CA) is expected to grow by 49.02% in the next year.
How sustainable is the dividend of MEDICAL FACILITIES CORP (DR.CA) stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.